3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
109
Endometrial Neoplasms
16
Neoplasm Metastasis
10
Polycystic Ovary Syndrome
9
Ovarian Neoplasms
7
Neoplasms
7
Advanced Breast Cancer
5
Triple Negative Breast Neoplasms
4
Prostatic Neoplasms
4
Fallopian Tube Neoplasms
4
Recurrence
3
Infertility
3
Carcinoma, Intraductal, Noninfiltrating
3
Breast Neoplasms, Male
3
Squamous Cell Carcinoma of Head and Neck
2
Progesterone Resistance
2
Neoplasms by Site
2
Hereditary Sensory and Autonomic Neuropathies
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Estrogen Receptor-positive Breast Cancer
2
Endometrial Hyperplasia
2
Cystadenocarcinoma, Serous
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Breast Cancer Metastatic
2
Breast Cancer Female
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Interventions
Carboplatin
9
pembrolizumab
7
Pemetrexed
7
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Radiation
4
Nivolumab
4
Bevacizumab
4
Platinum
3
Paclitaxel
3
Mastectomy, Segmental
3
Cisplatin
3
Biopsy
3
fludarabine phosphate
2
durvalumab
2
capmatinib
2
aldesleukin
2
Taxes
2
Radiotherapy, Conformal
2
Radiosurgery
2
Ipilimumab
2
Interleukin-2
2
Immunoglobulin G
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
Anterior Temporal Lobectomy
2
1,2-diaminocyclohexaneplatinum II citrate
2
veliparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Letrozole
×
1 year
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled